CSN Login
Members Online: 4

You are here

Phase I study on patients with oxi refractory/intolerant KRAS mutant CRC

coloCan
Posts: 1956
Joined: Oct 2009

announced this date by Calgary, Canada-based Oncolytics Biotech, which will consist of FOLFIRI (Leucovorin,5FU and Irinotecan)with this new thing called Reolysin (REO). For more info see www.prnewsire.com or
rttnews.com

Hope this helps someone

Subscribe to Comments for "Phase I  study on patients with oxi refractory/intolerant KRAS mutant CRC"